Effects of thromboxane synthetase inhibitor (OKY-046) on urinary prostaglandin excretion and renal function in streptozotocin-induced diabetic rat

Yuji Tajiri, Fumio Umeda, Toyoshi Inoguchi, Hajime Nawata

    Research output: Contribution to journalArticle

    15 Citations (Scopus)

    Abstract

    The present study was undertaken to evaluate the effects of a selective thromboxane synthetase inhibitor (OKY-046) on urinary prostaglandins (PGs) excretion and renal parameters such as endogenous creatinine clearance rate (Ccr) and urinary protein excretion in streptozotocin (STZ)-induced diabetic rats. STZ-diabetic rats were divided into two groups; one fed standard chow (DM1) and the other, standard chow mixed with 0.1% OKY-046 (DM2) for 24 weeks. Male Wistar rats were fed standard chow for 24 weeks as control (C). Urinary thromboxane B2 (TXB2) and 6-keto-PGF1α excretions significantly increased in STZ-induced diabetic rats (DM1 and DM2) compared with C after 24 weeks. The increased urinary TXB2 excretion in DM2 was significantly reduced (p < 0.05) compared with that in DM1 (261.1 ± 18.6 ng/gCr versus 380.0 ± 48.4 ng/gCr, mean ± SEM). No significant difference could be found in urinary protein excretion between DM1 and DM2, which was significantly higher in both diabetic groups than C after 12 and 24 weeks. Ccr in both DM1 and DM2 significantly increased (p < 0.05) compared with C after 12 weeks. In contrast, after 24 weeks, Ccr in DM1 fell down to 0.18 ± 0.02 mL/min 100 g body weight (BW), thus being significantly lower (p < 0.05) than that in C (0.27 ± 0.03 mL/min 100 g BW) and DM2 (0.25 ± 0.02 mL/min 100 g BW). Electron microscopic findings in diabetic rats after 24 weeks were the typical change of early diabetic nephropathy, whereas there were no obvious differences between DM1 and DM2. From these results, increased thromboxane A2 from renal origin (partly platelet origin) in STZ-induced diabetic rats appears quite likely to be involved in the pathogenesis of diabetic nephropathy, and the inhibition of TXA2 synthesis by OKY-046 was shown capable of preventing deterioration of renal function.

    Original languageEnglish
    Pages (from-to)126-132
    Number of pages7
    JournalJournal of Diabetes and Its Complications
    Volume8
    Issue number2
    DOIs
    Publication statusPublished - Jan 1 1994

    Fingerprint

    Thromboxane-A Synthase
    Streptozocin
    Prostaglandins
    Creatinine
    Thromboxane B2
    Body Weight
    Diabetic Nephropathies
    Kidney
    Thromboxane A2
    Wistar Rats
    Proteins
    Blood Platelets
    Renal Elimination
    ozagrel
    Electrons

    All Science Journal Classification (ASJC) codes

    • Internal Medicine
    • Endocrinology, Diabetes and Metabolism
    • Endocrinology

    Cite this

    Effects of thromboxane synthetase inhibitor (OKY-046) on urinary prostaglandin excretion and renal function in streptozotocin-induced diabetic rat. / Tajiri, Yuji; Umeda, Fumio; Inoguchi, Toyoshi; Nawata, Hajime.

    In: Journal of Diabetes and Its Complications, Vol. 8, No. 2, 01.01.1994, p. 126-132.

    Research output: Contribution to journalArticle

    @article{cc27976c81d041b093fa4271a60b3d12,
    title = "Effects of thromboxane synthetase inhibitor (OKY-046) on urinary prostaglandin excretion and renal function in streptozotocin-induced diabetic rat",
    abstract = "The present study was undertaken to evaluate the effects of a selective thromboxane synthetase inhibitor (OKY-046) on urinary prostaglandins (PGs) excretion and renal parameters such as endogenous creatinine clearance rate (Ccr) and urinary protein excretion in streptozotocin (STZ)-induced diabetic rats. STZ-diabetic rats were divided into two groups; one fed standard chow (DM1) and the other, standard chow mixed with 0.1{\%} OKY-046 (DM2) for 24 weeks. Male Wistar rats were fed standard chow for 24 weeks as control (C). Urinary thromboxane B2 (TXB2) and 6-keto-PGF1α excretions significantly increased in STZ-induced diabetic rats (DM1 and DM2) compared with C after 24 weeks. The increased urinary TXB2 excretion in DM2 was significantly reduced (p < 0.05) compared with that in DM1 (261.1 ± 18.6 ng/gCr versus 380.0 ± 48.4 ng/gCr, mean ± SEM). No significant difference could be found in urinary protein excretion between DM1 and DM2, which was significantly higher in both diabetic groups than C after 12 and 24 weeks. Ccr in both DM1 and DM2 significantly increased (p < 0.05) compared with C after 12 weeks. In contrast, after 24 weeks, Ccr in DM1 fell down to 0.18 ± 0.02 mL/min 100 g body weight (BW), thus being significantly lower (p < 0.05) than that in C (0.27 ± 0.03 mL/min 100 g BW) and DM2 (0.25 ± 0.02 mL/min 100 g BW). Electron microscopic findings in diabetic rats after 24 weeks were the typical change of early diabetic nephropathy, whereas there were no obvious differences between DM1 and DM2. From these results, increased thromboxane A2 from renal origin (partly platelet origin) in STZ-induced diabetic rats appears quite likely to be involved in the pathogenesis of diabetic nephropathy, and the inhibition of TXA2 synthesis by OKY-046 was shown capable of preventing deterioration of renal function.",
    author = "Yuji Tajiri and Fumio Umeda and Toyoshi Inoguchi and Hajime Nawata",
    year = "1994",
    month = "1",
    day = "1",
    doi = "10.1016/1056-8727(94)90062-0",
    language = "English",
    volume = "8",
    pages = "126--132",
    journal = "Journal of Diabetes and its Complications",
    issn = "1056-8727",
    publisher = "Elsevier Inc.",
    number = "2",

    }

    TY - JOUR

    T1 - Effects of thromboxane synthetase inhibitor (OKY-046) on urinary prostaglandin excretion and renal function in streptozotocin-induced diabetic rat

    AU - Tajiri, Yuji

    AU - Umeda, Fumio

    AU - Inoguchi, Toyoshi

    AU - Nawata, Hajime

    PY - 1994/1/1

    Y1 - 1994/1/1

    N2 - The present study was undertaken to evaluate the effects of a selective thromboxane synthetase inhibitor (OKY-046) on urinary prostaglandins (PGs) excretion and renal parameters such as endogenous creatinine clearance rate (Ccr) and urinary protein excretion in streptozotocin (STZ)-induced diabetic rats. STZ-diabetic rats were divided into two groups; one fed standard chow (DM1) and the other, standard chow mixed with 0.1% OKY-046 (DM2) for 24 weeks. Male Wistar rats were fed standard chow for 24 weeks as control (C). Urinary thromboxane B2 (TXB2) and 6-keto-PGF1α excretions significantly increased in STZ-induced diabetic rats (DM1 and DM2) compared with C after 24 weeks. The increased urinary TXB2 excretion in DM2 was significantly reduced (p < 0.05) compared with that in DM1 (261.1 ± 18.6 ng/gCr versus 380.0 ± 48.4 ng/gCr, mean ± SEM). No significant difference could be found in urinary protein excretion between DM1 and DM2, which was significantly higher in both diabetic groups than C after 12 and 24 weeks. Ccr in both DM1 and DM2 significantly increased (p < 0.05) compared with C after 12 weeks. In contrast, after 24 weeks, Ccr in DM1 fell down to 0.18 ± 0.02 mL/min 100 g body weight (BW), thus being significantly lower (p < 0.05) than that in C (0.27 ± 0.03 mL/min 100 g BW) and DM2 (0.25 ± 0.02 mL/min 100 g BW). Electron microscopic findings in diabetic rats after 24 weeks were the typical change of early diabetic nephropathy, whereas there were no obvious differences between DM1 and DM2. From these results, increased thromboxane A2 from renal origin (partly platelet origin) in STZ-induced diabetic rats appears quite likely to be involved in the pathogenesis of diabetic nephropathy, and the inhibition of TXA2 synthesis by OKY-046 was shown capable of preventing deterioration of renal function.

    AB - The present study was undertaken to evaluate the effects of a selective thromboxane synthetase inhibitor (OKY-046) on urinary prostaglandins (PGs) excretion and renal parameters such as endogenous creatinine clearance rate (Ccr) and urinary protein excretion in streptozotocin (STZ)-induced diabetic rats. STZ-diabetic rats were divided into two groups; one fed standard chow (DM1) and the other, standard chow mixed with 0.1% OKY-046 (DM2) for 24 weeks. Male Wistar rats were fed standard chow for 24 weeks as control (C). Urinary thromboxane B2 (TXB2) and 6-keto-PGF1α excretions significantly increased in STZ-induced diabetic rats (DM1 and DM2) compared with C after 24 weeks. The increased urinary TXB2 excretion in DM2 was significantly reduced (p < 0.05) compared with that in DM1 (261.1 ± 18.6 ng/gCr versus 380.0 ± 48.4 ng/gCr, mean ± SEM). No significant difference could be found in urinary protein excretion between DM1 and DM2, which was significantly higher in both diabetic groups than C after 12 and 24 weeks. Ccr in both DM1 and DM2 significantly increased (p < 0.05) compared with C after 12 weeks. In contrast, after 24 weeks, Ccr in DM1 fell down to 0.18 ± 0.02 mL/min 100 g body weight (BW), thus being significantly lower (p < 0.05) than that in C (0.27 ± 0.03 mL/min 100 g BW) and DM2 (0.25 ± 0.02 mL/min 100 g BW). Electron microscopic findings in diabetic rats after 24 weeks were the typical change of early diabetic nephropathy, whereas there were no obvious differences between DM1 and DM2. From these results, increased thromboxane A2 from renal origin (partly platelet origin) in STZ-induced diabetic rats appears quite likely to be involved in the pathogenesis of diabetic nephropathy, and the inhibition of TXA2 synthesis by OKY-046 was shown capable of preventing deterioration of renal function.

    UR - http://www.scopus.com/inward/record.url?scp=0027942325&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0027942325&partnerID=8YFLogxK

    U2 - 10.1016/1056-8727(94)90062-0

    DO - 10.1016/1056-8727(94)90062-0

    M3 - Article

    C2 - 8061349

    AN - SCOPUS:0027942325

    VL - 8

    SP - 126

    EP - 132

    JO - Journal of Diabetes and its Complications

    JF - Journal of Diabetes and its Complications

    SN - 1056-8727

    IS - 2

    ER -